Approach to the Patient With Treatment-resistant Acromegaly

Eva C. Coopmans, Aart J. Van Der Lely, Sebastian J.C.M.M. Neggers

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

11 Citaten (Scopus)


Although most tumors in patients with acromegaly are benign and are cured or controlled by surgery and/or first-generation somatostatin receptor ligands therapy, some can behave more aggressively and are resistant to these standard therapies. Acromegaly, if left untreated, is a rare and chronic disorder, commonly caused by a GH-producing pituitary adenoma and is associated with significant comorbidities and an increased mortality. Transsphenoidal surgery is considered the mainstay of acromegaly management, but medical therapy has an increasingly important role. However, disease activity is not fully controlled in a significant number of patients treated with surgery and/or high-dose first-generation somatostatin receptor ligand monotherapy. In these circumstances, therefore, repeated surgery, second-line medical therapy, and radiotherapy, alone or combined as multimodal therapeutic strategies should be considered, in a patient-centered perspective.

Originele taal-2Engels
Pagina's (van-tot)1759-1766
Aantal pagina's8
TijdschriftJournal of Clinical Endocrinology and Metabolism
Nummer van het tijdschrift6
StatusGepubliceerd - 17 mei 2022
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Approach to the Patient With Treatment-resistant Acromegaly'. Samen vormen ze een unieke vingerafdruk.

Citeer dit